Biopharma IPOs: Timing, capital and staying flexible
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.